Modified in vivo lung perfusion allows for prolonged perfusion without acute lung injury  by dos Santos, Pedro Reck et al.
E
T
/B
S
EVOLVING TECHNOLOGY/BASIC SCIENCEModified in vivo lung perfusion allows for prolonged perfusion
without acute lung injuryPedro Reck dos Santos, MD,a,b Ilker Iskender, MD,a,b Tiago Machuca, MD,a David Hwang, MD,a
Marc dePerrot, MSc, MD,a,b Mingyao Liu, MD,a,b Shaf Keshavjee, MSc, MD,a,b
Thomas K. Waddell, MSc, MD, PhD,a,b and Marcelo Cypel, MSc, MDa,bFrom th
Unive
Institu
M. Cyp
T.K.
Perfu
and d
Disclosu
Read at
Surge
Receive
public
Address
Unive
Toron
0022-52
Copyrig
http://dx
774Objectives: In vivo lung perfusion (IVLP) is an emergent strategy to treat lung metastases because it allows
localized delivery of chemotherapy with minimal systemic exposure. Previously, short-term (30 minutes)
IVLP resulted in variable efficacy and significant lung toxicity. We hypothesize that a modified IVLP strategy
derived from an ex vivo lung perfusion technique could minimize lung injury. Our objective was to demonstrate
the feasibility and safety of a modified prolonged (4 hours) IVLP.
Methods: Six Yorkshire pigs were used for the experiments. A thoracotomy was performed, the left pulmonary
artery and pulmonary veins were cannulated, and the left lung was isolated in situ. IVLP was performed at
normothermia for 4 hours using Steen Solution (XVIVO Perfusion, G€oteburg, Sweden) as perfusate. The
flow rate was 16% of estimated cardiac output and left atrial pressure was maintained between 3 and 5 mm
Hg. Perfusate was deoxygenated and supplied with CO2 to physiologic levels before entering the lungs.
A protective mode of ventilation was used. After IVLP, the left lung was allowed to reperfuse for additional
4 hours. Airway dynamics, gas exchange, and pulmonary vascular resistance were used to assess left lung
physiology. Histologic signs of lung injury were assessed before and after IVLP, and 4 hours after reperfusion.
Results: Lung function parameters were stable throughout the 4-hour IVLP and during reperfusion.
No significant histologic evidence of acute lung injury was observed.
Conclusions: Four hours of IVLP is feasible without adding significant lung injury. Prolonged perfusion
time and a protective protocol might provide safer and more efficacious treatment of pulmonary metastases.
(J Thorac Cardiovasc Surg 2014;147:774-82)Lungs can often be the only sites of dissemination of metas-
tases, and this is especially common for neoplasms such as
sarcomas and colorectal carcinomas. Lung metastasectomy
remains the most effective approach in this situation;
however, the 5-year survival of 20% to 40% associated
with this treatment is disappointing.1 One of the most
important factors related to this poor overall survival is
the intrathoracic recurrence of resected disease, which is
common.2,3 The presence of micrometastatic disease may
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The Journal of Thoracic and Cardiovascular Surgis not properly treated because it cannot be noticed during
surgery. The delivery of high-dose chemotherapy
exclusively to the lung within a closed system, via in vivo
lung perfusion (IVLP), can be an attractive strategy to
overcome this problem. IVLP allows for the selective deli-
very of therapy to the lungs, avoiding the systemic side
effects associated with drug administration while achieving
high concentrations of chemotherapy in the lung tissue.
Past clinical studies presented significant toxicity to the
lungs, including acute complications (noncardiogenic
lung edema and chemical pneumonitis) and chronic alter-
ations (decreased forced expiratory volume in 1 second
and diffusion capacity), and these were important factors
that limited the widespread use of this approach.4-6 It was
unclear from many of these studies whether the perfusion
procedure itself or the chemotherapy was the major
reason for the lung injury. Improved lung perfusion
technology and strategies have been described recently,
especially for lung transplantation. Based on our previous
experience with ex vivo lung perfusion (EVLP), lungs can
now be perfused and ventilated for several hours at
normothermic temperatures without inflicting lung
injury.7 With the knowledge learned from EVLP, we aimed
to develop a novel IVLP strategy to be used safely as a plat-
form for the local delivery of treatment strategies for the
prevention of pulmonary metastases recurrences.ery c February 2014
Abbreviations and Acronyms
EVLP ¼ ex vivo lung perfusion
IVLP ¼ in vivo lung perfusion
LA ¼ left atrium
PA ¼ pulmonary artery
PawP ¼ peak airway pressure
PVR ¼ pulmonary vascular resistance
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Animals
Six Yorkshire pigs weighing an average of 35 kg were used for all
experiments. All animals received humane care in compliance with the
Principles of Laboratory Animal Care formulated by the National Society
for Medical Research and the Guide for the Care of Laboratory Animals
published by the National Institutes of Health. The Animal Care
Committee of the Toronto General Research Institute approved this study.
Experimental Strategy
Animals were subjected to a 4-hour period of left lung IVLP followed
by a single-pass gravity-driven washout and additional 4 hours of
reperfusion. Ventilation and perfusion parameters were derived and
modified from the EVLP technique and are described in Table 1. At the
end of reperfusion, the animals were killed by exsanguination.
IVLP Procedure
After induction of general anesthesia, a tracheostomy was performed
and a 19-Fr left-sided double-lumen endotracheal tube was positioned to
allow measurement of the airway mechanics of the perfused lung
throughout the procedure. Ventilation was maintained with an intensive
care unit ventilator (Servo-I; Maquet Critical Care, Solna, Sweden)
according to the parameters listed in Table 1. A left posterolateral
thoracotomy was performed and the left azygous vein was ligated over
the descending aorta, with dissection carried toward the left pulmonary
artery (PA), which was fully mobilized. The next step was the mobilization
of the upper and lower left pulmonary veins. For this purpose, a dissection
plane was created between the left azygous vein and the left atrium (LA).
Proper identification of the mediastinal venous branch is important because
this facilitates the positioning of the LA clamp. The left main bronchus was
then dissected and isolated and the peribronchial tissue was stripped to
diminish bronchial circulation in the isolated lung circuit.
After dissection of these structures, 2 concentric purse-string sutures
were placed in the left PA and 1 purse-string suture in each left pulmonary
vein. Heparin 5000 IU (Sandoz, Quebec City, Canada) was administered
through a central venous line and a cannula (Cardioplegia Cannula
Antegrade, 13 Fr; Maquet Cardiopulmonary, Rastatt, Germany) was
inserted in the PA and snared. A right-angle cannula (Venous Catheter
OD 12 Fr; Maquet Cardiopulmonary) was then inserted in the upper and
lower left pulmonary veins (Figure 1). The venous cannulas were inserted
as close as possible to the junction of the pulmonary veins to the LA to pre-
vent selective cannulation of venous branches. Pediatric feeding tubes (5-
Fr) were used to monitor the pulmonary and LA pressures; the tubes were
inserted in the PA and in the left lower vein, respectively, and connected to a
monitor (SurgiVet; Smiths Medical, Norwell, Mass). Before IVLP initia-
tion, PA and LA vascular clamps were inserted to isolate the left lung
from the systemic circulation.
IVLP Circuit
The IVLP circuit is shown in Figure 1. The perfusate was circulated by
a centrifugal pump (Revolution; Sorin Group USA Inc, Arvada, Colo)The Journal of Thoracic and Capassing through a leukocyte depletion filter (LG-6 Leukocyte Reduction
Filter; Pall Corporation, Port Washington, NY) and a membrane gas
exchanger (Quadrox-i Oxygenator System; Maquet Cardiopulmonary
AG, Hirrlingen, Germany) before entering the left lung through the PA.
A filtered gas line for the gas exchange membrane was connected to an
H-size specialty gas mixture of oxygen (6%), carbon dioxide (8%), and
nitrogen (86%) (Praxair, Mississauga, Canada). This mixture deoxyge-
nates the perfusate and provides carbon dioxide to the inflow maintaining
PCO2 between 35 and 45 mm Hg (the gas was started at 1 L/min and was
adjusted to obtain these PCO2 levels). A heat exchanger (Sarns, Ann Arbor,
Mich) was connected to the membrane gas exchanger to maintain the
perfusate at 37C. PA flow was controlled by the centrifugal pump and
measured using an electromagnetic flow meter (Sorin Group, Munich,
Germany). The outflow perfusate was returned through the left atrial
cannulas to a hard-shell reservoir (Maquet Cardiopulmonary AG). The
height of the reservoir controlled LA pressure.
Priming the Circuit
The reservoir of the circuit was primed with 1.2 L of Steen Solution
(XVIVO Perfusion, G€oteburg, Sweden), which is a buffered dextran
containing an extracellular solution with an optimal colloid osmotic
pressure, developed for extracorporeal perfusion of lungs. In addition,
500 mg of methyl prednisolone (Solu-medrol; Pfizer, Kirkland, Canada),
1 g of cefazolin (Pharmaceutical Partners of Canada Inc, Richmond Hill,
Canada), and 5000 IU of heparin were added to the perfusate.
Perfusion Strategy
Perfusion was initiated at 37C, with continuous measurement of the
systemic, PA, and LA pressures, with a flow established according to the
estimated cardiac output of the animal. We used 16% of estimated cardiac
output to perfuse the left lung only. The rationale for this flow rate is that, in
the EVLP protocol, we perfuse both lungs with 40% of the calculated
cardiac output. From this value, approximately 60% of the flow
(ie, 24% of the entire cardiac output) is directed to the right lung
and 40% (ie, 16% of the cardiac output) to the left lung. Using these
calculations, usual flows to the left lung were 450 to 550 mL/min depend-
ing on animal weight and estimated cardiac output. To obtain these rates,
we used a strategy to gradually increase the flow, which consisted of a
3-step increment starting with 30% of the calculated flow for 10 minutes,
then moving to 60% for the next 10 minutes, and finally to 100%
(at full IVLP flow). Once PA pressure levels were obtained, we adjusted
the reservoir height of the perfusion circuit to maintain LA pressure
between 3 and 5 mm Hg.
Ventilation Strategy for Measurement of Left Lung
Function
During IVLP, oxygenation of the animal was performed by the right
lung exclusively. Using a double-lumen endotracheal tube, the right lung
was briefly excluded to assess pulmonary mechanics of the left lung
only. This was performed every hour during IVLP. After this measurement,
ventilation for both lungs was restarted, and a recruitment maneuver to a
Pawp of 25 cm H2O was performed to fully reexpand the right lung. It is
necessary to carefully control the oxygenation level of the animal because
hypoxia may appear promptly during right lung deflation.
Terminating IVLP and the Reperfusion Phase
After 4 hours of IVLP, venous cannulas were removed and washout was
administered in an anterograde fashion with 500 mL of a low potassium
dextran solution (Perfadex; XVIVO Perfusion), positioned 30 cm above
the animal, allowing a passive drainage of the effluent through the left pul-
monary veins by gravity. This washout period usually takes 10 to 15 mi-
nutes. The purse-string sutures in the pulmonary veins were then tied
and the LA and PA clamps were carefully removed. A review of therdiovascular Surgery c Volume 147, Number 2 775
TABLE 1. Ventilatory and perfusion strategies
Ventilatory parameters
Tidal volume 8 mL/kg
PEEP 5 cm H2O
Respiratory rate 16 breaths/min
FIO2 50%
Perfusion parameters
Flow rate 16% of cardiac output
Pulmonary artery pressure 10-15 mm Hg
Left atrium pressure 3-5 mm Hg
Temperature of perfusate 37C
PEEP, Positive end-expiratory pressure; FIO2, fraction of inspired oxygen. Para-
meters adapted from Cypel and colleagues.7
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identified and fixed. The pressure monitor catheters were left in place for
measurement of PA pressure in the reperfusion period and to collect
samples from the lower lobe vein.
Lung Function Assessments
Lung function was assessed before IVLP, hourly during IVLP, and after
reperfusion. Gas exchange function (PaO2/FIO2) using samples collectedFIGURE 1. Perfusion circuit. The perfusate is circulated by a centrifugal pump
of gas (oxygen, 6%; carbon dioxide, 8%; and nitrogen, 86%) to deoxygenate th
cyte filter and enters the lung through the left pulmonary artery. The temperature
the membrane gas exchanger. Pulmonary artery flow is controlled by the centrif
perfusate returns through the left pulmonary veins to a hard-shell reservoir, and th
appropriate range. Catheters in the left pulmonary artery and in the left lower vei
(ICU) ventilator provides ventilation to the lungs.
776 The Journal of Thoracic and Cardiovascular Surgfrom the left lower vein (before IVLP and during reperfusion) and
from the outflow of the perfusion circuit (during IVLP), airway
dynamics (airway peak and plateau pressures), lung compliance
(static and dynamic), and pulmonary vascular resistance (PVR) ([PA pres-
sure  LA pressure] 3 80/PA flow [dyn/s/cm5]) were evaluated. Gas ex-
change, PVR, peak airway pressure (PawP), and dynamic compliance
were recorded from both lungs, as well as from the perfused lung only.
Histology
Lung tissue biopsies were collected from the periphery of the lung
before and after IVLP, and 4 hours after reperfusion. Tissue samples
were fixed in 10% buffered formalin for 48 hours before being transferred
to 70% alcohol solution, embedded in paraffin, sectioned at 5-mm thick-
ness, stained by hematoxylin and eosin, and examined for pathologic
changes under light microscopy. The following criteria were used to obtain
the pathologic acute injury score: air space hemorrhage (presence of red
blood cells in the alveoli), vascular congestion (>75% of alveolar septum
occupied by red blood cells), fibrin in the alveoli, and the presence of
infiltrating white blood cells. These criteria were graded on a scale ranging
from normal appearance (0%), mild (10%), moderate (10%-50%), and
severe (>50%) abnormalities and scored from 0 to 3, respectively.
Radiologic assessment of the perfused lung, comparing values before
IVLP and at the end of the experiment, was used to assess for possible signs
of acute lung injury such as pulmonary infiltrates.passing through a membrane gas exchanger, which receives a combination
e perfusate and provide CO2 for the inflow. Flow is then directed to a leuko-
of the perfusate is maintained using a heat exchanger, which is connected to
ugal pump and measured using an electromagnetic flow meter. The outflow
e height of this reservoir is adjusted to have the drainage pressurewithin the
nmeasure PA and LA pressures, respectively. A standard intensive care unit
ery c February 2014
FIGURE 2. Left lung function during in vivo lung perfusion (IVLP). Lung function remained stable throughout the IVLP period. Lung oxygenation
function (P/F ratio, in mm Hg), pulmonary vascular resistance (in dyn/s/cm5), peak airway pressure (in cm H2O), and dynamic compliance
(in mL/cm H2O) all remained stable from 1 hour to 4 hours of IVLP (n ¼ 6; P> .05 between measures of lung function at all time points during
IVLP, using repeated measures analysis of variance).
dos Santos et al Evolving Technology/Basic ScienceStatistical Analysis
Results were analyzed using GraphPad Prism 5 (GraphPad Software
Inc, La Jolla, Calif). Data are expressed as mean  standard error of the
mean. For comparisons of lung ventilatory and perfusion parameters,
repeated measures analysis of variance was used. Posttest analysis
between each time point was performed with the Tukey test for multiple
comparisons. For comparisons between pathologic injury scores, the
Kruskal-Wallis test was used, and posttest analysis was performed using
the Dunn test.E
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The gas exchange (P/F ratio), PVR, and airway dynamics
(PawP and dynamic compliance) for the left lung remained
stable during 4-hour IVLP. The left lung had excellent
oxygenation levels during IVLP (P/F ratio was 510.8 
27.79 mm Hg at 1 hour and 546.4  21.77 mm Hg at
4 hours; P¼ .17) and no significant increase in PVR during
the IVLP was observed (PVR was 1.401 352.9 dyn/s/cm5
at 1 hour and 1.516 435.2 dyn/s/cm5 at 4 hours; P¼ .941)
(Figure 2). The P/F ratio in the left lower pulmonary vein
before IVLP was 325.2  24.45 mm Hg and at the end of
the procedure (4 hours IVLP þ 4 hours of blood
reperfusion), the P/F ratio was 433  37.42 mm Hg
(P ¼ .17). The PawP and the dynamic compliance of the
left lung remained stable during IVLP and reperfusion
(Figure 3). Gas exchange, airway dynamics, and PVR of
both lungs did not show any differences throughout the
procedure and are not described here.The Journal of Thoracic and CaThere were no differences in histologic acute lung injury
scores for 3 time points; representative images and scores
are shown in Figure 4. Chest radiographs at the beginning
of the procedure and at the end of 4 hours IVLP and
the additional 4 hours of reperfusion showed similar
radiographic patterns in the left lung, with no radiographic
signs of acute lung injury (Figure 5).
DISCUSSION
A successful strategy of IVLP for an extended period
of time without inflicting lung injury is described here.
This approach could potentially be used to lower the odds
of local recurrence after lung metastasectomy by adminis-
tering high-dose chemotherapy or targeted drug therapy to
the lung without deleterious systemic side effects.
The IVLP approach has been used recently with
encouraging results in a clinical setting8; a phase 1 clinical
study was performed using short-term (30 minutes) IVLP
with melphalan for resectable lung metastases from tumors
such as colorectal, kidney and sarcomas. Although lung
function was impaired at 1 month of follow-up, no major
long-term toxicity was found. It is important to note that
lung metastasectomy with IVLP could be performed with
results comparable with conventional lung metastasectomy
regarding postoperative quality of life scores.9
In the past 2 decades, experimental and clinical studies
on IVLP have shown the feasibility and reproducibility ofrdiovascular Surgery c Volume 147, Number 2 777
FIGURE 3. Left lung function after reperfusion. Compared with the baseline level, optimal oxygenation (P/F ratio) was found during in vivo lung perfu-
sion (IVLP) and after reperfusion. Peak airway pressure and dynamic compliance were also stable after reperfusion.
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metastases.10 Higher tissue concentrations were found
with this approach compared with systemic administration
of chemotherapy,11 and further experiments showed that
IVLP was effective in the treatment of lung metastases in
small animal models.12,13 However, despite the initial
optimism that was generated with these research
experiments, the subsequent clinical studies using short-
term IVLP to evaluate different drugs (doxorubicin,
cisplatin, and melphalan) and perfusate solutions (saline,
colloids, dextran, and blood) raised important concerns
with regard to acute lung toxicity and no improvement in
overall survival,5,14 hindering the broad application of this
technique. Most of these studies did not state whether the
toxicity was mainly related to the drug, perfusion
solution, or technique of IVLP applied.
Our study aim was to demonstrate that no measurable
lung injury occurs with this new IVLP strategy. Previous
large-animal studies have raised concerns about the
potential injury that the perfusion system may inflict apart
from the chemotherapeutic agent. Furrer and colleagues15
performed IVLP for 15 minutes in pigs, using flows ranging
from 70 to 120 mL/min, and found that controls animals
(IVLP without chemotherapy) had the same pattern of acute
lung injury in histology and chest radiographs compared
with animals perfused with doxorubicin. In another study,778 The Journal of Thoracic and Cardiovascular Surgpigs submitted to IVLP with and without chemotherapy
demonstrated higher histologic injury scores and impair-
ment of functional parameters compared with a sham
group.16 Histologic signs of hemorrhagic edemawere found
in both the control and melphalan-treated groups,17 raising
the question of the potential role that the perfusion circuit
may have in causing injury. More recently, Pages and
colleagues18 performed IVLP for 30 minutes in 50-kg
pigs, with a perfusion flow that ranged from 500 to 600
mL/min (adjusted to a PA pressure of around 25 mm Hg)
and found that the control group had even greater histologic
injury compared with lungs perfused with gemcitabine.
This again highlights that IVLP itself without drugs was
injurious.
With the objective to optimize previously reported IVLP
techniques, we derived many technical aspects from the
EVLP technique described by our group to preserve lungs
for extended periods outside the body, allowing for
repair and recovery of lung function for transplantation.
The clinical efficacy of the EVLP technique has already
been proved.19
Some key aspects of this modified IVLP technique
include
1. A perfusate solution with optimal osmotic pressure
designed specifically for lung perfusion. This is aery c February 2014
FIGURE 4. Histologic appearance of the lung before in vivo lung perfusion (IVLP), after prolonged IVLP, and after the additional 4 hours of reperfusion.
Lung histology was preserved at all time points. Injury score analyzed the presence of air space hemorrhage, vascular congestion, fibrin in the alveoli, and
infiltrating white blood cells. Each criterion was graded with a scale ranging from normal appearance (0%), mild (10%), moderate (10%-50%), and severe
(>50%) abnormalities and scored from 0 to 3, respectively.
dos Santos et al Evolving Technology/Basic Sciencesolution with high dextran content and albumin, leading
to optimal osmolality and oncotic pressure, and prevent-
ing the development of extravasation of intravascular
fluid to the interstitium and alveolar space. This solution
cleared pulmonary edema in injured donor lungs,
demonstrating its excellent properties for lung perfusion.
Previous and currently used solutions for IVLP (salineFIGURE 5. Chest radiograph comparing lungs before in vivo lung perfusion (I
preserved pattern in the left lung without signs of acute lung injury.
The Journal of Thoracic and Casolution, colloid solutions, blood) do not have the
same characteristics and have already been shown to
induce pulmonary edema in different animal models of
lung perfusion.20,21
2. A perfusion flow that reduces hydrostatic pressure,
diminishing the chance of lung edema development. In
accordance with our previous studies with EVLP, weVLP) and at the end of 4 hours of IVLP þ 4 hours of reperfusion showed a
rdiovascular Surgery c Volume 147, Number 2 779
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rendered a PA pressure of 10 to 15 mm Hg, which is
much lower than that described in other IVLP techniques
in which, most of the time, the flow is increased until the
PA pressure reaches 20 or 25 mm Hg. By maintaining a
lower hydrostatic pressure, the pulmonary vasculature is
protected. Steen and colleagues22 have used a PA pres-
sure of 20 mm Hg for EVLP and they have recognized
that after 1 hour of EVLP, pulmonary edema starts to
appear. In contrast, our studies have shown no edema
development for up to 12 hours of perfusion.7 Despite
this low-pressure strategy, we did achieve homogeneous
distribution of perfusion over time. The linear relation-
ship between perfusion flows, PA pressure levels, and
the development of pulmonary edema is well known23;
thus, our flow rates, between 450 and 550 mL/min under
PA pressure levels of 10 to 15 mm Hg, may have an
important role in protecting the lungs.
3. A positive and physiologic LA pressure preventing a
collapse and reopening phenomenon, and protecting
the vascular endothelium. Although previous descrip-
tions of IVLP models had controlled PA pressures,
they did not exert any control over the drainage pressure
in the pulmonary veins (drainage pressure). The system
described here drains the effluent to a hard-shell
reservoir where the drainage pressure can be perfectly
controlled and kept at physiologic levels of 3 to 5 mm
Hg. We believe this is an important element to protect
the lungs. Many physiologic experiments have been
performed demonstrating that either negative pressures
or supraphysiologic LA pressures induce pulmonary
edema and vascular failure.24,25
4. Protective mechanical ventilation with lower tidal
volumes, which prevent increases in alveolar perivascu-
lar pressure that can lead to an increase in PVR and lung
injury.26
5. Amean PA pressurewithin a range as close as possible to
physiologic levels (10-15 mm Hg), because increases in
the PA pressure levels may correlate with acute lung
injury in isolated lung perfusion.27 Some factors other
than pump flow may influence the PA pressure levels,
such as a low pH in the perfusate, the presence of high
tidal volumes, impaired left atrial drainage, and tech-
nical problems with the catheters measuring these pres-
sures. All these factors must be corrected to have a stable
and reliable PA pressure throughout the procedure.
6. The use of a centrifugal pump with better protection of
lung vasculature.
7. The use of a membrane gas exchanger supplied
with a special mixture of gas to maintain the physio-
logic levels of CO2 in the perfusate, which has
been shown to be an important component of lung
protection.28780 The Journal of Thoracic and Cardiovascular SurgDuring the development of this IVLP large-animal
model, some important intraoperative technical factors
were identified:
 Proper position of vascular clamps: considering the small
dimensions of the cannulas used to cannulate the left PA
and the pulmonary veins, a clamp that is not in the proper
position may generate obstruction or malfunctioning of
these cannulas, leading to high levels of PA and LA pres-
sure.
 Adequate drainage of the left pulmonary veins: it is
important to dissect and properly isolate the left
pulmonary veins. The dissection should be carried
toward the LA, which is a proper site to anchor the
purse-string sutures. A well-placed cannula (as close as
possible to the junction of the atrium and the respective
vein) is the best way to avoid obstruction of the outflow
drainage, allowing optimal drainage pressures.
 Bronchial circulation: important systemic flow is
drained to the reservoir during extended periods of
IVLP and this may lead to instability of the hemo-
dynamic status of the animal. Careful cauterization of
these vessels around the left main bronchus and snaring
of the bronchus if a left-side double-lumen tube is used
must be done to achieve complete isolation of this
circulation to the left lung.
The limitations of this study are the absence of other
groups with different perfusion strategies for comparison
and the absence of long-term follow-up. Although the
4-hour perfusion time may seem long for clinical applica-
tion, pharmacokinetics studies are now being performed
with different drugs to determine the potential advantages
of a prolonged perfusion time on tissue concentration and
distribution in this model. Experimental studies in small an-
imals have demonstrated that increased levels of chemo-
therapy in lung tissue were found with increases in IVLP
time.29 IVLP with a safe extended perfusion time may also
open up opportunities for other localized therapies that
require a longer exposure window such as gene therapy.30
In conclusion, this modified IVLP technique can be
performed safely, without evidence of acute lung injury.
Studies on the use of chemotherapy using the strategy
described here need to be performed. Some concepts that
were previously studied within an isolated lung perfusion
setting may be reevaluated in the future using this platform,
such as hyperthermic perfusion and multidrug medical
regimens. A reliable platform to perfuse an organ in situ
without inflicting damage may be an important step toward
the use of more efficacious conventional chemotherapy,
targeted therapies, or gene therapy aiming to prevent
recurrence or treat lung metastases. The results derived
from these studies will set the stage to establish a clinical
IVLP program at our institution.ery c February 2014
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Dr Paul E. Van Schil (Antwerp, Belgium). I would like to
thank the Association for the privilege of discussing this
excellent paper and I thank the authors for sending me the slides
in advance.
Isolated lung perfusion is an experimental technique to deliver
high-dose chemotherapy to the lung without systemic exposure in
order to obtain better drug targeting. A lot of experimental and,
recently, also clinical studies have been performed to evaluate
toxicity, pharmacokinetics, and efficacy. In fact, 1 of the first
clinical studies originated from Toronto, performed by Michael
Johnston, and published in 1995 in the Journal of Thoracic and
Cardiovascular Surgery. It is stimulating to see that the Toronto
group, having extensive experience with ex vivo lung perfusion,
has picked up experimental in vivo lung perfusion studies again.
The authors are to be congratulated for performing a difficult
experimental study. In our current clinical phase 2 study, which
we perform together with 3 thoracic surgical centers in The
Netherlands, a dose of 45 mg of melphalan is used with a perfusion
time of 30 minutes. In the present experimental study, the authors
demonstrate that in a pig model, perfusion times up to 4 hours are
feasible without any significant lung injury.
I have several questions for the authors and I will list them
separately. Why did you specifically choose Steen solution to
perform the lung perfusion, which is rarely used in clinical in
vivo perfusion studies, in contrast to transplantation?
Dr dos Santos.We used Steen solution because it is a solution
specially developed for lung perfusion and, because of the
increased oncotic pressure, it keeps the water in the intravascular
space and avoids lung edema.rdiovascular Surgery c Volume 147, Number 2 781
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SDr Van Schil. Did you temporarily occlude the arterial
bronchial circulation during perfusion?
Dr dos Santos. Yes. We try to dissect the bronchial circulation
as much as we can, because we noticed that if you do not dissect
and try to ligate these vessels, you are going to have a significant
leak from the bronchial circulation into the pulmonary circulation
and consequently to the circuit, and this might lead to hemody-
namic instability.
DrVan Schil.Regarding the lung injury, howwere the different
scores determined with a range from 0 to 12, and was this a
validated score?
Dr dos Santos. It is an injury score used by our pathologists at
Toronto General Hospital. I’m sorry, I don’t understand the
question.782 The Journal of Thoracic and Cardiovascular SurgDrVan Schil.Regarding the lung injury, youmake a distinction
between scores from 0 to 12. Was this a validated score? We are
very interested in that because we do not have a good scoring
system for lung injury during perfusion.
Dr dos Santos.My feeling is that it is a validated score, because
it is the same score that we have used for many acute lung injury
studies done in our institution. I hope that I’m answering your
question.
Dr Van Schil. Lastly, perfusion was done at normothermia.
Do you have any data on hyperthermic perfusion?
Dr dos Santos.We know that hyperthermia might increase the
uptake of drugs, and probably this is 1 variable that we are plan-
ning for future studies.
Dr Van Schil. Thank you.ery c February 2014
